logo
Sign in

RCKT Stock Price, Chart, Stats & News

Rocket Pharmaceuticals, Inc.
Save

Rocket Pharmaceuticals, Inc. (RCKT) does not currently pay a dividend.

295.66M
Market cap
–
Current P/E
–
Forward P/E

RCKT chart

Fundamentals

Gross margin
–
Operating margin
–
Pretax margin
–
Net margin
–
Effective tax rate
–
ROA
-67.52%
ROE
-65.76%
D/E
0.09x
Interest coverage ratio
-49.03x

RCKT valuation

P/E
–
P/S
–
P/B
1.51x
P/CF
-2.20x
P/FCF
-2.15x
P/OCF
-2.20x
PEG
-0.18x
EV multiple
-2.23x

About

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia.

Similar securities

Based on sector and market capitalization

Report issue